PMC:7187150 / 548-982 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T14","span":{"begin":36,"end":43},"obj":"Body_part"},{"id":"T15","span":{"begin":258,"end":265},"obj":"Body_part"},{"id":"T16","span":{"begin":297,"end":302},"obj":"Body_part"},{"id":"T17","span":{"begin":317,"end":322},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"To assess whether hrsACE2 — a decoy protein that has already been tested in phase I and II clinical trials — can inhibit the interaction between SARS-CoV-2 and ACE2, Josef Penninger, Ali Mirazimi, Nuria Montserrat and colleagues administered the recombinant protein to SARS-CoV-2-infected Vero E6 cells. Treatment of cells with hrsACE2 inhibited SARS-CoV-2 infection in a dose-dependent manner and attenuated propagation of the virus."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T9","span":{"begin":145,"end":153},"obj":"Disease"},{"id":"T10","span":{"begin":269,"end":277},"obj":"Disease"},{"id":"T11","span":{"begin":346,"end":354},"obj":"Disease"},{"id":"T12","span":{"begin":357,"end":366},"obj":"Disease"}],"attributes":[{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"To assess whether hrsACE2 — a decoy protein that has already been tested in phase I and II clinical trials — can inhibit the interaction between SARS-CoV-2 and ACE2, Josef Penninger, Ali Mirazimi, Nuria Montserrat and colleagues administered the recombinant protein to SARS-CoV-2-infected Vero E6 cells. Treatment of cells with hrsACE2 inhibited SARS-CoV-2 infection in a dose-dependent manner and attenuated propagation of the virus."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":28,"end":29},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T26","span":{"begin":49,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T27","span":{"begin":66,"end":72},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T28","span":{"begin":289,"end":302},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T29","span":{"begin":317,"end":322},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T30","span":{"begin":370,"end":371},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T31","span":{"begin":428,"end":433},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"To assess whether hrsACE2 — a decoy protein that has already been tested in phase I and II clinical trials — can inhibit the interaction between SARS-CoV-2 and ACE2, Josef Penninger, Ali Mirazimi, Nuria Montserrat and colleagues administered the recombinant protein to SARS-CoV-2-infected Vero E6 cells. Treatment of cells with hrsACE2 inhibited SARS-CoV-2 infection in a dose-dependent manner and attenuated propagation of the virus."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":36,"end":43},"obj":"Chemical"},{"id":"T2","span":{"begin":88,"end":90},"obj":"Chemical"},{"id":"T3","span":{"begin":258,"end":265},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"To assess whether hrsACE2 — a decoy protein that has already been tested in phase I and II clinical trials — can inhibit the interaction between SARS-CoV-2 and ACE2, Josef Penninger, Ali Mirazimi, Nuria Montserrat and colleagues administered the recombinant protein to SARS-CoV-2-infected Vero E6 cells. Treatment of cells with hrsACE2 inhibited SARS-CoV-2 infection in a dose-dependent manner and attenuated propagation of the virus."}

{"project":"LitCovid-sentences","denotations":[{"id":"T5","span":{"begin":0,"end":303},"obj":"Sentence"},{"id":"T6","span":{"begin":304,"end":434},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To assess whether hrsACE2 — a decoy protein that has already been tested in phase I and II clinical trials — can inhibit the interaction between SARS-CoV-2 and ACE2, Josef Penninger, Ali Mirazimi, Nuria Montserrat and colleagues administered the recombinant protein to SARS-CoV-2-infected Vero E6 cells. Treatment of cells with hrsACE2 inhibited SARS-CoV-2 infection in a dose-dependent manner and attenuated propagation of the virus."}

{"project":"LitCovid-PubTator","denotations":[{"id":"27","span":{"begin":160,"end":164},"obj":"Gene"},{"id":"28","span":{"begin":145,"end":155},"obj":"Species"},{"id":"29","span":{"begin":274,"end":288},"obj":"Disease"},{"id":"30","span":{"begin":346,"end":366},"obj":"Disease"},{"id":"31","span":{"begin":294,"end":296},"obj":"CellLine"}],"attributes":[{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Gene:59272"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Tax:2697049"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"MESH:C000657245"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C000657245"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"CVCL:4582"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"To assess whether hrsACE2 — a decoy protein that has already been tested in phase I and II clinical trials — can inhibit the interaction between SARS-CoV-2 and ACE2, Josef Penninger, Ali Mirazimi, Nuria Montserrat and colleagues administered the recombinant protein to SARS-CoV-2-infected Vero E6 cells. Treatment of cells with hrsACE2 inhibited SARS-CoV-2 infection in a dose-dependent manner and attenuated propagation of the virus."}